title: Dilemmas in the compassionate supply of investigational cancer drugs.
abstract: In Australia, patients who want to access medicines that are not yet approved have only two options: to enroll in a clinical trial if they are eligible, or obtain their medicine through 'compassionate supply', which is provided at the discretion of the manufacturer. In this article, we explore ethical issues associated with the provision of oncology medicines that are still in development, either prior to regulatory approval or government reimbursement.
authors.affiliation: Centre for Values, Ethics and Law in Medicine, School of Public Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
authors.forename: J R R
authors.initials: JR
authors.lastname: Lewis
authors.forename: W
authors.initials: W
authors.lastname: Lipworth
authors.forename: I
authors.initials: I
authors.lastname: Kerridge
authors.forename: E
authors.initials: E
authors.lastname: Doran
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001315:Australia; D035843:Biomedical Research; D057176:Compassionate Use Trials / Q000941:ethics* / Q000706:statistics & numerical data; D015507:Drugs, Investigational / Q000627:therapeutic use*; D006297:Health Services Accessibility / Q000941:ethics*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D028701:Patient Rights / Q000941:ethics; D018579:Patient Selection / Q000941:ethics*
chemical_list: D000970:Antineoplastic Agents; D015507:Drugs, Investigational
keywords: ethics; evidence-based medicine; health services accessibility; oncology